Short Interest in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Expands By 38.1%

Avalo Therapeutics, Inc. (NASDAQ:AVTX) was the recipient of a large growth in short interest in the month of September. As of September 15th, there was short interest totalling 59,500 shares, a growth of 38.1% from the August 31st total of 43,100 shares. Based on an average daily volume of 16,200 shares, the short-interest ratio is presently 3.7 days. Currently, 0.6% of the shares of the company are short sold.

Hedge Funds Weigh In On Avalo Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in AVTX. Affinity Asset Advisors LLC bought a new position in shares of Avalo Therapeutics during the first quarter valued at $218,000. Ikarian Capital LLC bought a new position in Avalo Therapeutics during the first quarter worth $1,015,000. Finally, Logos Global Management LP bought a new position in Avalo Therapeutics during the second quarter worth $6,722,000. Institutional investors own 87.06% of the company’s stock.

Avalo Therapeutics Stock Performance

NASDAQ AVTX traded down $0.15 during trading on Friday, reaching $9.20. The company’s stock had a trading volume of 13,147 shares, compared to its average volume of 246,098. Avalo Therapeutics has a 12 month low of $3.95 and a 12 month high of $45.10. The firm has a 50 day moving average price of $9.68 and a 200 day moving average price of $11.15.

Avalo Therapeutics (NASDAQ:AVTX) last issued its quarterly earnings results on Monday, August 12th. The company reported ($14.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($6.70) by ($7.37). Avalo Therapeutics had a negative return on equity of 306.52% and a negative net margin of 1,639.50%. Analysts anticipate that Avalo Therapeutics will post -7.78 earnings per share for the current year.

About Avalo Therapeutics

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.